Iovance Biotherp Stock Price, News & Analysis

Iovance Biotherapeutics (NASDAQ: IOVA), a biotech company specializing in novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced its participation in three upcoming conferences. The company's senior leadership will be presenting at:

1. Wells Fargo Healthcare Conference in Boston on September 4, 2024, at 3:45 p.m. ET
2. Baird Global Healthcare Conference in New York on September 10, 2024, at 2:35 p.m. ET
3. H.C. Wainwright Global Investment Conference in New York on September 11, 2024, at 11:00 a.m. ET

Live and archived webcasts of these presentations will be accessible on the Iovance website at https://ir.iovance.com/news-events/events-presentations.

Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced the granting of inducement stock options and restricted stock units. On August 15, 2024, the company approved awards covering 289,710 shares of common stock to 24 new, non-executive employees under its 2021 Inducement Plan.

The stock options have an exercise price of $10.67, matching the closing price of Iovance's common stock on the grant date. Both stock options and restricted stock units follow a three-year vesting schedule, with one-third vesting on the first anniversary of the employee's start date and the remaining shares vesting in eight quarterly installments over the following two years, contingent on continued employment.

Iovance Biotherapeutics reported strong Q2 2024 results, with total product revenue of $31.1 million. This includes $12.8 million from Amtagvi, their newly launched TIL therapy for advanced melanoma, and $18.3 million from Proleukin. The company provided guidance for Q3 2024 total product revenue of $53-$55 million, FY 2024 revenue of $160-$165 million, and FY 2025 revenue of $450-$475 million.

Iovance has $449.6 million in cash as of July 24, 2024, expected to fund operations into early 2026. The Amtagvi launch is progressing well, with over 55 patients infused since April 2024. The company is expanding its manufacturing capacity and advancing its clinical pipeline in multiple indications.

Iovance Biotherapeutics (NASDAQ: IOVA), a biotech company specializing in novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced its upcoming second quarter and first half 2024 financial results conference call. The event is scheduled for Thursday, August 8, 2024, at 4:30 p.m. ET. Management will present the financial results and provide a corporate update during the call.

Investors and interested parties can access the live audio webcast by registering at the provided link. The webcast will also be archived and available for one year in the Investors section of the Iovance website. This event offers an opportunity for stakeholders to gain insights into the company's financial performance and recent developments in its innovative cancer therapies.

Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company focused on developing novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced the grant of inducement stock options to 19 new, non-executive employees. The grants, approved on July 18, 2024, cover an aggregate of 106,010 shares of Iovance's common stock.

These awards were granted under Iovance's 2021 Inducement Plan, which was adopted on September 22, 2021, and subsequently amended. Each stock option has an exercise price of $8.31, matching the closing price of Iovance's common stock on the grant date. The options vest over a three-year period, with one-third vesting on the first anniversary of the employee's start date and the remaining shares vesting in eight quarterly installments over the next two years.

Iovance Biotherapeutics has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for lifileucel, a novel TIL cell therapy, to treat adults with unresectable or metastatic melanoma previously treated with a PD-1 blocker and, if applicable, a BRAF inhibitor. If approved, lifileucel would be the first and only therapy available for this indication across the EU. This submission follows positive clinical trial results from the C-144-01 study. The EMA’s Committee for Medicinal Products for Human Use (CHMP) is expected to issue a decision in 2025. Further global submissions are planned in Canada, the UK, and Australia by 2025, aiming to address over 20,000 annual advanced melanoma cases in these regions.

Iovance Biotherapeutics (NASDAQ: IOVA) announced on June 21, 2024, that it approved inducement stock options for 43 new non-executive employees on June 20, 2024. The stock options cover an aggregate of 187,650 shares of common stock, each with an exercise price of $7.97, the closing price on the grant date. These options vest over three years, with one-third vesting on the first anniversary of the employee's start date and the remainder vesting quarterly over the next two years. The inducement grants are made under Iovance's 2021 Inducement Plan, which aligns with Nasdaq Listing Rule 5635(c)(4).

Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer, announced its participation in several upcoming conferences and events.

Key events include the TD Cowen 5th Annual Oncology Innovation Summit on May 28, 2024, a virtual ASCO Investor/Analyst event on May 31, 2024, the Jefferies Global Healthcare Conference on June 6, 2024, the Goldman Sachs Global Healthcare Conference on June 10, 2024, and the Iovance 2024 Annual Meeting on June 11, 2024.

These events will feature presentations and discussions by senior leadership, with webcasts available at the company's investor relations website.

Iovance Biotherapeutics presented new clinical data for lifileucel combined with pembrolizumab in frontline advanced melanoma at the ASCO 2024 Annual Meeting. The IOV-COM-202 trial showed a 65% objective response rate (ORR) and a 30% complete response rate, with nearly all responses ongoing at a median follow-up of 21.7 months. The results support the ongoing TILVANCE-301 Phase 3 trial. Lifileucel's safety profile as a one-time treatment was favorable compared to continuous regimens. Early interim analysis of ORR could expedite regulatory approval.